| Literature DB >> 11049772 |
Y Chen1, C Scieux, V Garrait, G Socié, V Rocha, J M Molina, D Thouvenot, F Morfin, L Hocqueloux, L Garderet, H Espérou, F Sélimi, A Devergie, G Leleu, M Aymard, F Morinet, E Gluckman, P Ribaud.
Abstract
Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed among 196 allogeneic stem cell transplant recipients within a 29-month period. Recipients of unrelated stem cell transplants were at higher risk. All patients received foscarnet; 8 subsequently received cidofovir. Strains were initially foscarnet-resistant in 3 patients and secondarily so in 4 patients. In vitro resistance to acyclovir or foscarnet was associated with clinical failure of these drugs; however, in vitro susceptibility to foscarnet was associated with complete response in only 5 of 7 patients. No strain from any of the 7 patients was resistant in vitro to cidofovir; however, only 3 of 7 patients achieved complete response. Therefore, acyclovir- and/or foscarnet-resistant HSV-1 infections after allogeneic stem cell transplantation have become a concern; current strategies need to be reassessed and new strategies must be evaluated in this setting.Entities:
Mesh：
Substances：
Year: 2000 PMID： 11049772 DOI： 10.1086/314052
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079